Marshall Early, DO
Vascular Surgery · Midland, TXNPI 1942528138
Payments from drug & device makers
Across 137 payments — averaging $63.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$3K
- Silk Road Medical, Inc.$1K
- W. L. Gore & Associates, Inc.$741
- GE HealthCare$717
- Medtronic$439
- Penumbra, Inc.$328
- plus $2K from 33 others
What the payments were for
- Travel & lodging$1,35116%
- Food & beverage$4,43851%
- Other$2,88933%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 5 | $3,038 |
| Silk Road Medical, Inc. | 14 | $1,095 |
| W. L. Gore & Associates, Inc. | 14 | $741 |
| GE HealthCare | 6 | $717 |
| Medtronic(2 entities) | 16 | $439 |
| Penumbra, Inc. | 2 | $328 |
| Johnson & Johnson | 6 | $289 |
| Tactile Systems Technology Inc | 11 | $225 |
| Intuitive Surgical | 3 | $220 |
| Inari Medical, Inc. | 10 | $199 |
| Abiomed | 9 | $154 |
| AstraZeneca | 1 | $135 |
| Argentum Medical | 1 | $102 |
| Stryker | 3 | $93 |
| Endologix LLC | 1 | $90 |
| Boston Scientific | 4 | $86 |
| Davol Inc. | 3 | $83 |
| Artivion, Inc. | 1 | $55 |
| Acell, Inc. | 3 | $51 |
| Lemaitre Vascular, Inc. | 2 | $45 |
| Integra Lifesciences Corporation | 2 | $45 |
| Reflow Medical Inc | 1 | $44 |
| Innovation Technologies Inc | 1 | $41 |
| Smith+Nephew | 2 | $40 |
| TELA Bio, Inc. | 2 | $36 |
| Vertex | 1 | $30 |
| Conmed Corporation | 1 | $30 |
| TEI Biosciences Inc | 1 | $28 |
| Potrero Medical, Inc. | 1 | $26 |
| Cordis US CORP. | 1 | $24 |
| Portola Pharmaceuticals, LLC | 1 | $22 |
| Kerecis Limited | 1 | $19 |
| Bolton Medical Inc | 1 | $19 |
| Pfizer | 1 | $19 |
| Innocoll Pharmaceuticals Limited | 1 | $18 |
| Baxter Healthcare | 1 | $15 |
| Heron Therapeutics, Inc. | 1 | $15 |
| AbbVie | 1 | $13 |
| Elucent Medical | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaCure 1470 Pro$3,011
- ENROUTE Transcarotid Neuroprotection System$780
- ENROUTE Transcarotid Stent System$780
- ENHANCE Transcarotid Peripheral Access Kit$780
- ENROUTE 0.014 Guidewire$780
- GORE TAG Thoracic Branch Endoprosthesis$183
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$183
- Penumbra System$166
- Indigo System$162
- LOKELMA$135
- Echelon Flex$112
- Da Vinci Surgical System$106
How this compares
$8,678 in reported general payments places this provider in the 55th percentile of 347 vascular surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $19,303 |
| ClopidogrelClopidogrel Bisulfate | 106 | $868 |
| Tramadol Hcl | 76 | $494 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $175 |
| Atorvastatin Calcium | 16 | $50 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $19 | $19,30327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 347 vascular surgery providers in Texas.
Other vascular surgery in Midland
- Mazin FotehAustin$2.5M
- Alan LumsdenHouston$2.4M
- Gregory PearlDallas$2.3M
- Gustavo OderichHouston$999K
- Michael SiahDallas$838K
- Stephen HohmannDallas$587K
- Dennis GableDallas$547K
- Carlos TimaranDallas$527K
- Samuel LeonardHouston$431K
- Ali AzizzadehHouston$387K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.